Ken Griffin Nu Cana PLC Transaction History

Citadel Advisors LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$0.26 - $0.42 $14,752 - $23,830	-56,739 Reduced 38.84%	89,344 $23,000
Q4 2023 Feb 14, 2024	BUY	$0.26 - $0.8 $37,981 - $116,866	146,083 New	146,083 $43,000
Q1 2023 May 15, 2023	SELL	$0.76 - $1.69 $76,834 - $170,855	-101,098 Reduced 88.87%	12,662 $12,000
Q4 2022 Feb 14, 2023	BUY	$0.66 - $27.41 $33,151 - $1.38 Million	50,229 Added 79.06%	113,760 $75,000
Q3 2022 Nov 14, 2022	BUY	$0.62 - $26.13 $18,508 - $780,032	29,852 Added 88.64%	63,531 $66,000
Q2 2022 Aug 15, 2022	BUY	$0.59 - $1.06 $19,870 - $35,699	33,679 New	33,679 $24,000
Q1 2022 May 16, 2022	SELL	$0.74 - $3.27 $106,856 - $472,188	-144,400 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$2.02 - $2.9 $291,688 - $418,760	144,400 New	144,400 $0
Q1 2020 May 15, 2020	SELL	$4.02 - $9.05 $64,118 - $144,347	-15,950 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.55 - $8.48 $32,950 - $50,345	5,937 Added 59.29%	15,950 $97,000
Q3 2018 Nov 13, 2018	SELL	$20.12 - $26.86 $25,371 - $33,870	-1,261 Reduced 11.19%	10,013 $0
Q2 2018 Aug 10, 2018	SELL	$19.0 - $29.84 $11,552 - $18,142	-608 Reduced 5.12%	11,274 $0
Q1 2018 May 11, 2018	SELL	$10.04 - $28.25 $119,275 - $335,610	-11,880 Reduced 50.0%	11,882 $225,000
Q4 2017 Feb 09, 2018	SELL	$10.0 - $18.72 $425,670 - $796,854	-42,567 Reduced 64.18%	23,762 $240,000
Q3 2017 Nov 09, 2017	BUY	$16.15 - $18.37 $1.07 Million - $1.22 Million	66,329	66,329 $1.22 Million

3.34M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $133M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.